ELAPRASE 6mg (Idursulfase Vials) 6mg/3ml

ELAPRASE 6mg (Idursulfase) is an enzyme replacement therapy for mucopolysaccharidosis II (MPS II), a rare genetic disorder. This 6mg/3ml vial formulation supports lysosomal enzyme activity. Store between 2-8°C to maintain potency. Always follow healthcare provider guidance.

Strength

6mg/3ml

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Sanofi

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

ELAPRASE 6mg is used to treat mucopolysaccharidosis type II, also known as Hunter syndrome. It helps manage symptoms by replacing deficient enzymes in patients with this inherited metabolic condition. This therapy supports normal cellular function and may reduce disease progression. It is prescribed for individuals with confirmed MPS II diagnoses.

Side Effects

ELAPRASE 6mg works by supplying the missing enzyme that breaks down complex sugars in the body. Patients may experience improved mobility and reduced organ enlargement over time. Some individuals report better endurance during daily activities. Effects vary based on individual response and treatment duration.

Precautions & Warnings

ELAPRASE 6mg requires careful handling and storage at 2-8°C to maintain effectiveness. Always check the vial for particles or discoloration before use. Administer under medical supervision to monitor for infusion-related reactions. Keep the product in its original packaging to protect from light.

Avoid Interactions

No specific drug interactions have been established for ELAPRASE 6mg. However, caution is advised when combining with other intravenous therapies. Always inform your healthcare provider about all medications being taken. Monitor for infusion-related reactions, especially with concurrent use of other injectable treatments.

Frequently Asked Questions

ELAPRASE 6mg is used to treat mucopolysaccharidosis type II (Hunter syndrome) by replacing deficient enzymes.

ELAPRASE 6mg should be stored between 2-8°C and protected from light.

Administration of ELAPRASE 6mg should be supervised by a healthcare professional.

Common effects may include infusion-related reactions or mild discomfort at the injection site.

Prescription medications like ELAPRASE 6mg require medical authorization and are not typically sold online without proper oversight.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.